本人刘学，1962 年出生，中国国籍，北京大学光华管理学院博士，现任北 京大学光华管理学院组织与战略系教授、首药控股(北京)股份有限公司、广西东 呈酒店管理集团股份有限公司独立董事职务。 普蕊斯（上海）医药科技开发股份有限公司 独立董事刘学先生 2024 年度述职报告 各位股东及股东代表： 本人作为普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"） 第三届董事会的独立董事，在任职期间严格按照《公司法》《证券法》《上市公司 独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》等有关法律法规以及《公司章程》《公司独立董事工作制度》 等的有关规定，在 2024 年度工作中，定期了解公司的财务和运营情况，忠实履 行独立董事的相关职责，积极出席公司召开的相关会议，认真仔细审阅各项会议 议案及相关材料，对公司重大事项发表独立意见，充分发挥独立董事的作用，努 力维护公司和全体股东特别是中小股东的合法权益。现将 2024 年度任职期间本 人履行独立董事的职责情况报告如下： 一、基本情况 | 独立董事 | 应出席会 | 亲自出席 | 委托出席 | 缺席会议 | 是否连续两次未 ...

普蕊斯（上海）医药科技开发股份有限公司 公司章程 普蕊斯（上海）医药科技开发 股份有限公司章程 二零二五年四月 | 第一章 | 总则 1 | | --- | --- | | 第二章 | 经营宗旨和经营范围 2 | | 第三章 | 股份 2 | | 第一节 | 股份 2 | | 第二节 | 股份增减和回购 3 | | 第三节 | 股份转让 5 | | 第四章 | 股东和股东大会 5 | | 第一节 | 股东 5 | | 第二节 | 股东大会的一般规定 9 | | 第三节 | 股东大会的召集 13 | | 第四节 | 股东大会的提案与通知 14 | | 第五节 | 股东大会的召开 15 | | 第六节 | 股东大会的表决和决议 18 | | 第五章 | 董事会 22 | | 第一节 | 董事 22 | | 第二节 | 董事会 25 | | 第六章 | 总经理及其他高级管理人员 29 | | 第七章 | 监事会 31 | | 第一节 | 监事 32 | | 第二节 | 监事会 32 | | 第八章 | 财务会计制度、利润分配和审计 33 | | 第一节 | 财务会计制度 34 | | 第二节 | 内部审计 36 | ...

普蕊斯（上海）医药科技开发股份有限公司 独立董事黄华生先生 2024 年度述职报告 各位股东及股东代表： 本人作为普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"）第 三届董事会的独立董事，在任职期间严格按照《公司法》《证券法》《上市公司独 立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》等有关法律法规以及《公司章程》《公司独立董事工作制度》 等的有关规定，在 2024 年度工作中，定期了解公司的财务和运营情况，忠实履 行独立董事的相关职责，积极出席公司召开的相关会议，认真仔细审阅各项会议 议案及相关材料，对公司重大事项发表独立意见，充分发挥独立董事的作用，努 力维护公司和全体股东特别是中小股东的合法权益。现将 2024 年度任职期间本 人履行独立董事的职责情况报告如下： 一、基本情况 本人黄华生，1969 年出生，中国国籍，中国政法大学博士，现任江西财经 大学法学院教授、博士生导师，华润博雅生物制药集团股份有限公司独立董事。 本人未在公司担任除独立董事外的其他职务，并与公司及控股股东、实际控 制人不存在直接或者间接利害关系，或者其他可能影响本人进行独立客观 ...

普蕊斯（上海）医药科技开发股份有限公司董事会 普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"）董事会根 据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等要求，并结合独立董事出具的《独立董事独 立性自查情况表》，认为公司独立董事不存在任何妨碍其进行独立客观判断的关 系，不存在影响独立董事独立性的情况，符合《上市公司独立董事管理办法》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法 律法规及《公司章程》中关于独立董事的任职资格及独立性的要求。 普蕊斯（上海）医药科技开发股份有限公司董事会 2025 年 4 月 29 日 关于独立董事独立性情况的专项意见 ...

普蕊斯（上海）医药科技开发股份有限公司 独立董事廖县生先生 2024 年度述职报告 各位股东及股东代表： 本人作为普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"） 第三届董事会的独立董事，在任职期间严格按照《公司法》《证券法》《上市公司 独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》等有关法律法规以及《公司章程》《公司独立董事工作制度》 等的有关规定，在 2024 年度工作中，定期了解公司的财务和运营情况，忠实履 行独立董事的相关职责，积极出席公司召开的相关会议，认真仔细审阅各项会议 议案及相关材料，对公司重大事项发表独立意见，充分发挥独立董事的作用，努 力维护公司和全体股东特别是中小股东的合法权益。现将 2024 年度任职期间本 人履行独立董事的职责情况报告如下： 一、基本情况 本人廖县生，1968 年出生，中国国籍，大学本科，高级会计师、注册会计 师，现任江西中审会计师事务所有限责任公司董事长、中文天地出版传媒集团股 份有限公司独立董事、江西赣能股份有限公司独立董事、恒邦财产保险股份有限 公司独立董事等职务。 本人未在公司担任除独立董事外的其他职务 ...

Financial Performance - The company's revenue for Q1 2025 was ¥176,466,917.68, a decrease of 4.37% compared to ¥184,532,679.41 in the same period last year[5] - Net profit attributable to shareholders was ¥7,431,617.71, down 67.32% from ¥22,737,202.98 year-on-year[5] - Basic and diluted earnings per share decreased by 76.32% to ¥0.09 from ¥0.38 in the same period last year[5] - The company's net profit for the current period is 7,431,617.71, a decrease of 67.24% compared to 22,737,202.98 in the previous period[24] - Operating profit for the current period is 7,410,767.37, down 71.73% from 26,187,330.39 in the previous period[24] - Total revenue from operating activities is 167,160,562.28, compared to 170,027,073.63 in the previous period, reflecting a decrease of 1.10%[27] Cash Flow - The net cash flow from operating activities was -¥36,061,657.52, representing a decline of 321.73% compared to -¥8,550,816.03 in the previous year[5] - The net cash flow from investment activities decreased by 72.01% to ¥22,709,137.00, mainly due to a reduction in the redemption of financial products[11] - The company experienced a 53.87% decrease in net cash flow from financing activities, attributed to increased cash payments for leases[11] - The net cash flow from operating activities is -36,061,657.52, worsening from -8,550,816.03 in the previous period[27] - The net cash flow from investment activities is 22,709,137.00, down from 81,122,056.14 in the previous period[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,416,710,312.18, a decrease of 0.90% from ¥1,429,620,491.24 at the end of the previous year[5] - Total liabilities decreased from CNY 256.48 million to CNY 236.14 million during the same period[22] - Cash and cash equivalents at the end of the period amount to 473,169,430.70, down from 564,307,218.74 in the previous period[28] Shareholder Information - The largest shareholder, Shihezi Xitai Equity Investment Partnership, holds 18.58% of shares, totaling 14,773,473 shares[14] - The second-largest shareholder, Shihezi Ruixin Equity Investment Partnership, owns 8.05% of shares, amounting to 6,397,560 shares[14] - The total number of shares held by the top 10 shareholders is significant, with the largest three shareholders collectively holding over 34% of the company[14] - The company has a total of 31,995,562 restricted shares at the beginning of the period, with 5,460 shares released and 40,875 shares added, resulting in 32,030,977 restricted shares at the end of the period[16] - The release of restricted shares is scheduled for May 17, 2025, for several major shareholders[16] - The top 10 unrestricted shareholders include Shanghai Guanyu Investment Development Co., holding 5,474,040 shares, and other notable investors[14] - The total number of shares held by the top 10 unrestricted shareholders is 9,000,000 shares, indicating a concentrated ownership structure[14] Operational Highlights - The company faced pressure on gross margin and net margin due to intensified industry competition and a decline in new contract amounts in 2024[18] - As of the end of the reporting period, the total number of employees was 4,277, with over 4,050 being professional staff, serving more than 960 clinical trial institutions[18] - The company has undertaken over 3,800 international and domestic SMO projects, with 2,250 projects currently in execution[18] Research and Development - The company incurred research and development expenses of 9,059,623.94, an increase of 4.56% from 8,664,189.05 in the previous period[24] Future Plans - The actual controller plans to increase shareholding by CNY 6 million to CNY 9 million within six months from the announcement date[19] - The company completed the repurchase and cancellation of 5,460 restricted shares, reducing the total share capital from 79,508,000 shares to 79,502,540 shares[19]

Dividend Distribution - The company plans to distribute a cash dividend of 1.00 RMB per 10 shares to all shareholders, based on a total of 79,502,540 shares[3]. - The company plans to distribute a cash dividend of ¥1.50 per 10 shares for the 2024 semi-annual profit distribution, totaling ¥11,926,200, with no capital increase from capital reserves[165]. - For the 2023 annual profit distribution, the company will distribute a cash dividend of ¥1.66 per 10 shares, totaling ¥10,152,560, and will increase capital stock by 3 shares for every 10 shares held, resulting in a total increase of 18,348,000 shares[165]. - The total cash dividend represents 100% of the total distributable profit of 407,213,029.03 yuan for the year[168]. - The cash dividend distribution aligns with the company's growth stage and significant capital expenditure plans, ensuring a minimum of 20% cash dividend in profit distribution[168]. Financial Performance - The company's operating revenue for 2024 was ¥803,728,904.44, representing a 5.75% increase from ¥760,042,604.88 in 2023[17]. - The net profit attributable to shareholders for 2024 decreased by 21.01% to ¥106,429,303.29 from ¥134,729,838.37 in 2023[17]. - The net profit after deducting non-recurring gains and losses for 2024 was ¥83,473,192.75, down 26.88% from ¥114,154,580.17 in 2023[17]. - The total assets at the end of 2024 were ¥1,429,620,491.24, an increase of 4.59% from ¥1,366,819,029.33 at the end of 2023[17]. - The net assets attributable to shareholders at the end of 2024 were ¥1,173,140,830.63, up 8.56% from ¥1,080,595,266.47 at the end of 2023[17]. - The company reported a basic earnings per share of ¥1.35 for 2024, down 21.51% from ¥1.72 in 2023[17]. - The company's gross profit margin for the service industry was 24.38%, with a year-on-year decrease of 6.03%[57]. - The company achieved revenue of CNY 803.73 million, a year-on-year increase of 5.75%, while net profit attributable to shareholders decreased by 21.01% to CNY 106.43 million[51]. Market and Industry Trends - The company is focused on expanding its market presence and enhancing its product offerings through new technologies and research[3]. - Global pharmaceutical R&D spending is projected to increase from $163 billion in 2023 to $190 billion in 2024, with R&D as a percentage of sales exceeding 25% for the first time[27]. - In 2024, Chinese pharmaceutical companies are expected to achieve a historic breakthrough in License-out transactions, totaling $51.9 billion[28]. - The National Medical Products Administration (NMPA) received 19,563 drug registration applications in 2024, a year-on-year increase of 5.73%, with 3,073 new drug clinical trial applications (IND) and 549 new drug marketing authorization applications (NDA), reflecting a 16.81% increase[29]. - The NMPA approved 48 Class I innovative drugs in 2024, marking a 20% increase and a historical high[29]. Corporate Governance and Compliance - The company is dedicated to maintaining high standards of corporate governance and compliance with relevant regulations[3]. - The company emphasizes the importance of risk awareness regarding forward-looking statements in the annual report[3]. - The company has established a robust brand reputation and customer trust through its specialized service capabilities and extensive project execution experience[44]. - The company has a complete and independent business system, ensuring operational autonomy from its controlling shareholders[123]. - The company has established specialized committees under the board to provide scientific and professional advice for decision-making[123]. - The company has implemented a "Quality and Return Dual Improvement" action plan, although specific details were not disclosed[120]. Research and Development - The company operates in the clinical research outsourcing segment, focusing on enhancing trial execution efficiency and data quality through a data-driven approach[26]. - The company aims to become a leading data-driven innovative clinical research service provider in China, facilitating faster access to new drugs for patients[37]. - The company has developed a digital quality management and risk control system, enhancing operational efficiency and data security, certified by ISO27001[50]. - Research and development expenses increased by 3.13% to ¥35,837,987.32, primarily due to increased R&D investments[64]. - Investment in R&D for new technologies increased by 15%, amounting to ¥200 million, focusing on innovative healthcare solutions[116]. Operational Efficiency - The company is committed to improving clinical trial execution efficiency and quality by employing professional teams with medical and nursing backgrounds[39]. - The company has established a standardized project management system, ensuring efficient execution of clinical trial protocols, with 162 national and provincial inspections and 5 international inspections in 2024, all without major findings[45][46]. - The company has implemented a project management system for clinical trials, aiming to enhance efficiency and reduce costs[65]. - The company has integrated innovative technologies to enhance project execution efficiency, reducing clinical trial strategy construction time from several months to approximately one week[54]. - The company is focused on providing high-quality clinical services and enhancing customer experience through tailored project execution services[94]. Employee and Talent Management - The company has a comprehensive training system, providing hundreds of hours of training to ensure the professional development of its employees[49]. - The company emphasizes a competitive and fair salary system to attract and retain talent, incorporating performance-based incentives and stock options[160]. - Employee compensation accounted for 86.49% of the total operating costs, increasing by 20.63% year-on-year[59]. - The company has a dedicated internal audit department that ensures the authenticity and completeness of financial information[125]. - The company emphasizes talent development as a strategic priority, aiming to build a skilled workforce to support its growth[108]. Risk Management - The company faces risks related to potential declines in demand for pharmaceutical research services, which could adversely affect its business and financial performance[96][97]. - The company acknowledges risks from unexpected events, natural disasters, and pandemics that could adversely affect its operations and financial performance[113]. - The company has implemented a risk assessment process that dynamically identifies and analyzes risks, adjusting response strategies accordingly[177]. - The company must comply with GCP quality management requirements during clinical trials, and any lapses could lead to service quality issues and regulatory scrutiny[103]. - The execution cycle of project contracts is long, and delays or early terminations can negatively impact revenue and profitability[101]. Shareholder Engagement - The company actively listens to investor feedback and maintains strong investor relations management[122]. - The company held three shareholder meetings during the reporting period, all convened by the board, with all proposals passed legally and effectively[122]. - The company has improved the convenience of voting for minority shareholders by combining on-site and online voting methods[122]. - The company has established a market value management system to enhance investment value and investor returns, approved by the board on April 25, 2025[119]. - The company has committed to maintaining transparency and accuracy in its financial reporting and governance practices[132]. Strategic Initiatives - The company plans to explore the application of artificial intelligence and new technologies in clinical trial execution to improve efficiency[95]. - The company plans to continue its market expansion and product development strategies in the upcoming quarters[134]. - The company is committed to improving its profit distribution policy to enhance investor return mechanisms[200]. - The company has committed to avoiding any direct or indirect competition with its controlling shareholders and related parties[189]. - The company plans to enhance operational management and internal controls to improve overall profitability and efficiency in fund usage[200].

证券代码：301257 证券简称：普蕊斯 公告编号：2025-013 普蕊斯（上海）医药科技开发股份有限公司 关于实际控制人增持股份计划时间过半的公告 公司实际控制人赖春宝先生保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 重要内容提示： 1、普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"）于 2025 年 1 月 14 日披露了《关于实际控制人增持股份计划的公告》（公告编号：2025- 002），公司实际控制人、董事长赖春宝先生计划自本次增持计划公告发布之日 起 6 个月内，通过包括但不限于集中竞价、大宗交易等方式增持公司股份，增持 计划金额不低于人民币 600 万元且不超过人民币 900 万元（均含本数，下同）。 2、增持计划的进展情况：截至本公告披露日，赖春宝先生的增持计划实施 时间已过半。自 2025 年 1 月 15 日至 2025 年 4 月 15 日期间，赖春宝先生通过深 圳证券交易所交易系统以集中竞价方式累计增持公司股份 54,500 股，占公司总 股本的 0.07%，增持金额 ...

普蕊斯（上海）医药科技开发股份有限公司 详式权益变动报告书 上市公司名称：普蕊斯（上海）医药科技开发股份有限公司 股票上市地点：深圳证券交易所 股票简称：普蕊斯 股票代码：301257 信息披露义务人：赖春宝 住所：上海市浦东新区*** 信息披露义务人之一致行动人（一）：石河子市玺泰股权投资合伙企业 （有限合伙） 住所：新疆石河子开发区北四东路 37 号 2-227 室 信息披露义务人之一致行动人（二）：石河子市睿新股权投资合伙企业 （有限合伙） 住所：新疆石河子开发区北四东路 37 号 5-84 室 信息披露义务人之一致行动人（三）：石河子市睿泽盛股权投资有限公司 住所：新疆石河子市开发区北八路 21 号 20206 号 1 信息披露义务人之一致行动人（四）：赖小龙 住所：上海市浦东新区*** 三、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 四、本次股东权益变动是根据本报告书所载明的资料进行的。本信息披露义 务人没有委托或者授权其他任何人提供未在本报告书列载的信息和对本报告书 做出任何解释或者说明。 五、信息披露义务人承诺本权益 ...